Aegis Capital Lifts PT on Oramed Pharma (ORMP) to $30 Ahead of ORMD-0801 Phase 2a Data
Tweet Send to a Friend
Aegis Capital boosts its price target on Oramed Pharmaceuticals, Inc. (Nasdaq: ORMP) from $25 to $30, while maintaining its Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE